{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T09:56:25Z","timestamp":1719568585786},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n<jats:title>Hintergrund<\/jats:title>\n<jats:p>Die Therapie der Polyneuropathie beinhaltet die symptomatische Behandlung sensibler, motorischer und autonomer Funktionsst\u00f6rungen.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Ziel<\/jats:title>\n<jats:p>Der Beitrag soll einen \u00dcberblick \u00fcber aktuelle Therapieempfehlungen bei Polyneuropathie geben. Der Fokus liegt dabei auf der Schmerztherapie.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Material und Methoden<\/jats:title>\n<jats:p>Basierend auf einer Literaturrecherche werden die aktuellen Empfehlungen zur Therapie diskutiert.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Ergebnisse<\/jats:title>\n<jats:p>Mittel der ersten Wahl zur Therapie von Schmerzen bei Polyneuropathie sind die an Kalziumkan\u00e4len ansetzenden Antikonvulsiva Gabapentin und Pregabalin sowie die Antidepressiva Amitriptylin und Duloxetin. Alternativ k\u00f6nnen bei lokalisierten Beschwerden topische Therapeutika eingesetzt werden. In Einzelf\u00e4llen kann der Einsatz von Opioiden sowie anderen Antidepressiva und Antikonvulsiva erwogen werden. Limitiert wird die Therapie im Allgemeinen durch Nebenwirkungen vor allem zentralnerv\u00f6ser Art.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Schlussfolgerung<\/jats:title>\n<jats:p>Generell sollte die Therapie multimodal erfolgen und die Behandlung weiterer Beschwerden umfassen. Bei der Auswahl der Schmerzmedikation sollten Komorbidit\u00e4ten, Patientenalter und Nebenwirkungen ber\u00fccksichtigt werden. Eine Stratifizierung der Patienten anhand des Ph\u00e4notyps k\u00f6nnte dabei helfen, das bestm\u00f6gliche Therapieansprechen zu erzielen.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00108-020-00739-7","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T14:03:22Z","timestamp":1580997802000},"page":"270-276","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapie der Polyneuropathie \u2013 autonome Symptome und Schmerzen"],"prefix":"10.1007","volume":"61","author":[{"given":"J.","family":"Sachau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-C.","family":"Fabig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"739_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams\u00a0D, Gonzalez-Duarte\u00a0A, O\u2019Riordan\u00a0WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"739_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw261","author":"R Aiyer","year":"2016","unstructured":"Aiyer\u00a0R, Barkin\u00a0RL, Bhatia\u00a0A (2016) Treatment of neuropathic pain with venlafaxine: a systematic review. Pain Med. https:\/\/doi.org\/10.1093\/pm\/pnw261","journal-title":"Pain Med"},{"key":"739_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S1474-4422(16)00017-X","volume":"15","author":"N Attal","year":"2016","unstructured":"Attal\u00a0N, de Andrade\u00a0DC, Adam\u00a0F et al (2016) Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet Neurol 15:555\u2013565. https:\/\/doi.org\/10.1016\/S1474-4422(16)00017-X","journal-title":"Lancet Neurol"},{"key":"739_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S1474-4422(10)70143-5","volume":"9","author":"R Baron","year":"2010","unstructured":"Baron\u00a0R, Binder\u00a0A, Wasner\u00a0G (2010) Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9:807\u2013819. https:\/\/doi.org\/10.1016\/S1474-4422(10)70143-5","journal-title":"Lancet Neurol"},{"key":"739_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-57487-4","volume-title":"Praktische Schmerzmedizin, Interdisziplin\u00e4re Diagnostik \u2013 multimodale Therapie","author":"R Baron","year":"2019","unstructured":"Baron\u00a0R, Koppert\u00a0W, Strumpf\u00a0M, Willweber-Strumpf\u00a0A (2019) Praktische Schmerzmedizin, Interdisziplin\u00e4re Diagnostik \u2013 multimodale Therapie, 4.\u00a0Aufl. Springer, Berlin, Heidelberg","edition":"4"},{"key":"739_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/j.pain.0000000000000753","volume":"158","author":"R Baron","year":"2017","unstructured":"Baron\u00a0R, Maier\u00a0C, Attal\u00a0N et al (2017) Peripheral neuropathic pain: a\u00a0mechanism-related organizing principle based on sensory profiles. Pain 158:261\u2013272. https:\/\/doi.org\/10.1097\/j.pain.0000000000000753","journal-title":"Pain"},{"key":"739_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson\u00a0MD, Waddington-Cruz\u00a0M, Berk\u00a0JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"key":"739_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3238\/arztebl.2016.0616","volume":"113","author":"A Binder","year":"2016","unstructured":"Binder\u00a0A, Baron\u00a0R (2016) The pharmacological therapy of chronic neuropathic pain. Dtsch Arztebl Int 113:616\u2013625. https:\/\/doi.org\/10.3238\/arztebl.2016.0616","journal-title":"Dtsch Arztebl Int"},{"key":"739_CR9","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","volume":"155","author":"DT Demant","year":"2014","unstructured":"Demant\u00a0DT, Lund\u00a0K, Vollert\u00a0J, Maier\u00a0C, Segerdahl\u00a0M, Finnerup\u00a0NB, Jensen\u00a0TS, Sindrup\u00a0S (2014) The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a\u00a0randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 155:2263\u20132273. https:\/\/doi.org\/10.1016\/j.pain.2014.08.014","journal-title":"Pain"},{"key":"739_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup\u00a0NB, Attal\u00a0N, Haroutounian\u00a0S et al (2015) Pharmacotherapy for neuropathic pain in adults: a\u00a0systematic review and meta-analysis. Lancet Neurol 14:162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(14)70251-0","journal-title":"Lancet Neurol"},{"key":"739_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/brain\/awy329","volume":"142","author":"BTA de Greef","year":"2019","unstructured":"de Greef\u00a0BTA, Hoeijmakers\u00a0JGJ, Geerts\u00a0M et al (2019) Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a\u00a0randomized controlled trial. Brain 142:263\u2013275. https:\/\/doi.org\/10.1093\/brain\/awy329","journal-title":"Brain"},{"key":"739_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jpain.2009.09.019","volume":"11","author":"WR Kennedy","year":"2010","unstructured":"Kennedy\u00a0WR, Vanhove\u00a0GF, Lu\u00a0S\u2011P et al (2010) A randomized, controlled, open-label study of the long-term effects of NGX-4010, a\u00a0high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J\u00a0Pain 11:579\u2013587. https:\/\/doi.org\/10.1016\/j.jpain.2009.09.019","journal-title":"J Pain"},{"key":"739_CR13","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.3390\/ijms18122626","volume":"18","author":"W Kim","year":"2017","unstructured":"Kim\u00a0W, Chung\u00a0Y, Choi\u00a0S et al (2017) Duloxetine protects against oxaliplatin-induced neuropathic pain and spinal neuron hyperexcitability in rodents. IJMS 18:2626. https:\/\/doi.org\/10.3390\/ijms18122626","journal-title":"IJMS"},{"key":"739_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/pme.12728","volume":"16","author":"SE Lakhan","year":"2015","unstructured":"Lakhan\u00a0SE, Velasco\u00a0DN, Tepper\u00a0D (2015) Botulinum toxin\u2011A for painful diabetic neuropathy: a meta-analysis. Pain Med 16:1773\u20131780. https:\/\/doi.org\/10.1111\/pme.12728","journal-title":"Pain Med"},{"key":"739_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","author":"MPT Lunn","year":"2014","unstructured":"Lunn\u00a0MPT, Hughes\u00a0RAC, Wiffen\u00a0PJ (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007115.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"739_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1185\/03007995.2013.792246","volume":"29","author":"C Maihofner","year":"2013","unstructured":"Maihofner\u00a0C, Heskamp\u00a0M\u2011L (2013) Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12\u00a0weeks after a\u00a0single application of capsaicin 8\u202f% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin 29:673\u2013683. https:\/\/doi.org\/10.1185\/03007995.2013.792246","journal-title":"Curr Med Res Opin"},{"key":"739_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/j.1532-2149.2013.00415.x","volume":"18","author":"CG Maih\u00f6fner","year":"2014","unstructured":"Maih\u00f6fner\u00a0CG, Heskamp\u00a0M\u2011L (2014) Treatment of peripheral neuropathic pain by topical capsaicin: impact of pre-existing pain in the QUEPP-study. Eur J Pain 18:671\u2013679. https:\/\/doi.org\/10.1002\/j.1532-2149.2013.00415.x","journal-title":"Eur J Pain"},{"key":"739_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008242.pub3","author":"RA Moore","year":"2015","unstructured":"Moore\u00a0RA, Derry\u00a0S, Aldington\u00a0D et\u00a0al (2015) Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD008242.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"739_CR19","doi-asserted-by":"publisher","first-page":"CD012182","DOI":"10.1002\/14651858.CD012182.pub2","volume":"3","author":"M M\u00fccke","year":"2018","unstructured":"M\u00fccke\u00a0M, Phillips\u00a0T, Radbruch\u00a0L et al (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 3:CD12182. https:\/\/doi.org\/10.1002\/14651858.CD012182.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"739_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.clinthera.2017.02.010","volume":"39","author":"F van Nooten","year":"2017","unstructured":"van Nooten\u00a0F, Treur\u00a0M, Pantiri\u00a0K et al (2017) Capsaicin 8\u202f% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther 39:787\u2013803.e18. https:\/\/doi.org\/10.1016\/j.clinthera.2017.02.010","journal-title":"Clin Ther"},{"key":"739_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/toxins9090260","author":"J Park","year":"2017","unstructured":"Park\u00a0J, Park\u00a0HJ (2017) Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel). https:\/\/doi.org\/10.3390\/toxins9090260","journal-title":"Toxins (Basel)"},{"key":"739_CR22","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.2147\/DDDT.S142630","volume":"11","author":"G Pickering","year":"2017","unstructured":"Pickering\u00a0G, Martin\u00a0E, Tiberghien\u00a0F et\u00a0al (2017) Localized neuropathic pain: an expert consensus on local treatments. Drug Des Devel Ther 11:2709\u20132718. https:\/\/doi.org\/10.2147\/DDDT.S142630","journal-title":"Drug Des Devel Ther"},{"key":"739_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.neuroscience.2016.06.029","volume":"338","author":"L-A Roeckel","year":"2016","unstructured":"Roeckel\u00a0L\u2011A, Le Coz\u00a0G\u2011M, Gav\u00e9riaux-Ruff\u00a0C, Simonin\u00a0F (2016) Opioid-induced hyperalgesia: cellular and molecular mechanisms. Neuroscience 338:160\u2013182. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.06.029","journal-title":"Neuroscience"},{"key":"739_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.toxicon.2018.01.017","volume":"147","author":"Y Safarpour","year":"2018","unstructured":"Safarpour\u00a0Y, Jabbari\u00a0B (2018) Botulinum toxin treatment of pain syndromes\u2014an evidence based review. Toxicon 147:120\u2013128. https:\/\/doi.org\/10.1016\/j.toxicon.2018.01.017","journal-title":"Toxicon"},{"key":"739_CR25","volume-title":"Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen, S2k-Leitlinie","author":"T Schlereth","year":"2019","unstructured":"Schlereth\u00a0T (2019) Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen, S2k-Leitlinie"},{"key":"739_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3238\/arztebl.2018.083","volume":"115","author":"C Sommer","year":"2018","unstructured":"Sommer\u00a0C, Geber\u00a0C, Young\u00a0P et\u00a0al (2018) Polyneuropathies. Dtsch Arztebl Int 115:83\u201390. https:\/\/doi.org\/10.3238\/arztebl.2018.083","journal-title":"Dtsch Arztebl Int"},{"key":"739_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2377-8-29","volume":"8","author":"A Sultan","year":"2008","unstructured":"Sultan\u00a0A, Gaskell\u00a0H, Derry\u00a0S, Moore\u00a0RA (2008) Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 8:29. https:\/\/doi.org\/10.1186\/1471-2377-8-29","journal-title":"BMC Neurol"},{"key":"739_CR28","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1097\/j.pain.0000000000000935","volume":"158","author":"J Vollert","year":"2017","unstructured":"Vollert\u00a0J, Maier\u00a0C, Attal\u00a0N et\u00a0al (2017) Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations. Pain 158:1446\u20131455. https:\/\/doi.org\/10.1097\/j.pain.0000000000000935","journal-title":"Pain"},{"key":"739_CR29","doi-asserted-by":"publisher","first-page":"CD007938","DOI":"10.1002\/14651858.CD007938.pub4","volume":"6","author":"PJ Wiffen","year":"2017","unstructured":"Wiffen\u00a0PJ, Derry\u00a0S, Bell\u00a0RF et\u00a0al (2017) Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 6:CD7938. https:\/\/doi.org\/10.1002\/14651858.CD007938.pub4","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00739-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-020-00739-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00739-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:34:14Z","timestamp":1612485254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-020-00739-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s00108-020-00739-7","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,6]]},"assertion":[{"value":"6 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Sachau erhielt Reise- und \u00dcbernachtungskostenerstattungen von Alnylam Pharmaceuticals und Pfizer. Au\u00dferdem erhielt sie ein Vortragshonorar von Gr\u00fcnenthal GmbH. S.-C.\u00a0Fabig erhielt ein Vortragshonorar von Gr\u00fcnenthal GmbH. S.\u00a0Rehm erhielt ein Vortragshonorar von Bayer Vital GmbH sowie Reisekostenerstattung von Gr\u00fcnenthal GmbH. R.\u00a0Baron erh\u00e4lt finanzielle Zuwendungen f\u00fcr Forschungsvorhaben von Pfizer Pharma GmbH, Genzyme GmbH, Gr\u00fcnenthal GmbH, Mundipharma Research GmbH und Co. KG, Novartis Pharma GmbH, Alnylam Pharmaceuticals Inc., Zambon GmbH. Mitglied des EU-Projekts Nummer 633491: DOLORisk. Mitglied der Innovative Medicines Initiative (IMI) Europain Collaboration (777500). Bundesministerium f\u00fcr Bildung und Forschung (BMBF): Verbundprojekt: Fr\u00fchdetektion von Schmerzchronifizierung (NoChro; 13GW033GC). Deutscher Forschungsverbund Neuropathischer Schmerz (01EM0903). Er wurde f\u00fcr wissenschaftliche Fortbildungen von Pfizer Pharma GmbH, Genzyme GmbH, Gr\u00fcnenthal GmbH, Mundipharma, Sanofi Pasteur, Medtronic Inc. Neuromodulation, Eisai Co. Ltd., Lilly GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Astellas Pharma GmbH, Desitin Arzneimittel GmbH, Teva GmbH, Bayer-Schering, MSD GmbH, Seqirus Australia Pty. Ltd, Novartis Pharma GmbH, TAD Pharma GmbH, Gr\u00fcnenthal SA Portugal, Sanofi-Aventis Deutschland GmbH, Agentur Brigitte S\u00fcss, Gr\u00fcnenthal Pharma AG Schweiz, Gr\u00fcnenthal B.V. Niederlande honoriert. Au\u00dferdem erhielt er Honorare f\u00fcr Beratert\u00e4tigkeiten von Pfizer Pharma GmbH, Genzyme GmbH, Gr\u00fcnenthal GmbH, Mundipharma Research GmbH und Co. KG, Allergan, Sanofi Pasteur, Medtronic, Eisai, Lilly GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Astellas Pharma GmbH, Novartis Pharma GmbH, Bristol-Myers Squibb, Biogen Idec, AstraZeneca GmbH, Merck, AbbVie, Daiichi Sankyo, Glenmark Pharmaceuticals S.A., Seqirus Australia Pty. Ltd, Teva Pharmaceuticals Europe Niederlande, Teva GmbH, Genentech, Mundipharma International Ltd. UK, Astellas Pharma Ltd. UK, Galapagos NV, Kyowa Kirin GmbH, Vertex Pharmaceuticals Inc., Biotest AG, Celgene GmbH, Desitin Arzneimittel GmbH, Regeneron Pharmaceuticals Inc. USA, Theranexus DSV CEA Frankreich, Abbott Products Operations AG Schweiz, Bayer AG, Gr\u00fcnenthal Pharma AG Schweiz, Mundipharma Research Ltd. UK, Akcea Therapeutics Germany GmbH, Asahi Kasei Pharma Corporation, AbbVie Deutschland GmbH & Co. KG, Air Liquide Sante International Frankreich, Alnylam Germany GmbH, Lateral Pharma Pty Ltd, Hexal AG, Ethos Srl Italien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}